Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

Gastroenterology. 1992 Jun;102(6):2155-60. doi: 10.1016/0016-5085(92)90348-3.

Abstract

Six of 237 (2.5%) patients with chronic viral hepatitis who were treated with recombinant interferon alfa developed thyroid disease while on treatment. Three patients developed hyperthyroidism, two of whom developed detectable levels of thyroid-stimulating immunoglobulin; three patients developed hypothyroidism in association with high titers of antithyroglobulin and/or antimicrosomal antibodies. The thyroid disease did not remit when interferon therapy was stopped, and all six patients required definitive therapy for the thyroid disease. These findings suggest that a small proportion of patients treated with interferon alfa develop autoimmune reactions and can develop autoimmune thyroid disease.

MeSH terms

  • Adult
  • Autoimmune Diseases / etiology*
  • Chronic Disease
  • Female
  • Hepatitis, Viral, Human / therapy*
  • Humans
  • Interferon Type I / adverse effects*
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Thyroid Diseases / etiology*
  • Thyrotropin / blood

Substances

  • Interferon Type I
  • Recombinant Proteins
  • Thyrotropin